Hypertensive pregnancy disorders and future coronary artery disease
Hypertensive pregnancy disorders and future coronary artery disease
批准号:
10188609
负责人:
VESNA D GAROVIC
金额:
$52.61万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-09-01 至 2023-06-30
关键词:
AffectAgeAge-YearsAgingAtherosclerosisAtrial FibrillationBackCardiac Surgery proceduresCardiovascular systemCaringCause of DeathCessation of lifeClinicalCodeCohort StudiesCoronary ArteriosclerosisCoronary Artery BypassCountyDataDeath RateDiagnosisDiagnosticDiseaseEarly DiagnosisEpidemiologyEventFemaleFutureGoalsGoldHeart failureKnowledgeLeadMedical Record LinkageMedical RecordsMenopauseMethodologyMinnesotaMorbidity - disease rateMyocardial InfarctionNested Case-Control StudyOnset of illnessOutcomePatient Self-ReportPostmenopausePre-EclampsiaPregnancyPrevalencePreventionProteinuriaPublishingRecording of previous eventsRecordsReportingResearchResearch DesignResourcesRiskRisk FactorsSeveritiesSourceStrokeSystemTaxusTestingTimeTreatment EfficacyUnited StatesWomanWomen&aposs Rolebasecardiovascular healthcardiovascular risk factorclinical careclinical practicecohortdisabilitydisorder riskendothelial dysfunctionepidemiology studyexperiencefetalfollow-uphormone therapyimprovedlongitudinal datasetmalemenmodifiable riskmortalitynext generationnormotensivenovelparitypercutaneous coronary interventionpopulation basedpregnancy disorderprospectiverisk predictionscreening guidelinessexsynergismtooltreatment strategy
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
Coronary artery disease (CAD) is the leading cause of death and disability among women in the United States.
It became apparent in the 1980s that the decline of cardiovascular mortality in men was not accompanied by
the same rate of decline in women. The reasons for these differences may relate to worsening of the overall
CAD risk profile for aging in women compared to men, which may be further potentiated by sex-based
disparities in cardiovascular care: women have been both under-evaluated for CAD and under-treated for
modifiable risk factors. In addition, female sex-specific conditions, such as hypertensive pregnancy disorders
(HPD), together with menopause and hormone therapy, may contribute to those differences. Approximately
6%-8% of pregnancies are affected by HPD, which remains a leading cause of both maternal and fetal
morbidity and mortality worldwide. HPD cover a spectrum of conditions, most notably preeclampsia, a
pregnancy-specific hypertensive disorder further characterized by systemic endothelial dysfunction and
proteinuria.
Our overarching hypothesis is that a history of HPD in general, and preeclampsia in particular, represents a
unique risk factor that is independent of traditional risk factors for future coronary artery disease (CAD) events,
including myocardial infarction, coronary artery bypass grafting and percutaneous coronary intervention (Aim
1); is associated with more severe atherosclerotic disease at CAD event (Aim 2); and is related to increasing
cardiovascular morbidity and death among women with CAD (Aim 3).
There are no studies to date of the association between a history of HPD/preeclampsia and CAD that confirm
both exposure and outcome based on accepted clinical criteria, and that stratify the outcome based on the
severity of exposure while controlling for known risk factors occurring before, during, and after the affected
pregnancies. This proposal will cover current gaps in knowledge by testing these associations using the unique
population-based records-linkage system of the Rochester Epidemiology Project (REP). We will include all
female residents of Olmsted County, Minnesota who were identified through existing cohorts and REP-based
sources, and who had an incident CAD event from 2002-2017, supplemented with cohorts of incident heart
failure and atrial fibrillation that will be used to ascertain subsequent cardiovascular outcomes. We will perform
extensive medical record reviews to confirm the diagnoses of HPD by using validated criteria for the
retrospective diagnoses of HPD. The results of the proposed research may open new venues for early
detection, prevention, diagnosis, and treatment of CAD in women.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The KAPP-Sen Tissue Mapping Center Collaborative
-
批准号:10701907
-
项目类别:
-
资助金额:$270.0万
-
财政年份:2021
-
负责人:VESNA D GAROVIC
-
依托单位:
2021 Physiology in Focus: The Role of Sex Hormones, Genetics and Gender in Physiology & Medicine
-
批准号:10319292
-
项目类别:
-
资助金额:$1.5万
-
财政年份:2021
-
负责人:VESNA D GAROVIC
-
依托单位:
The KAPP-Sen Tissue Mapping Center Collaborative
-
批准号:10376627
-
项目类别:
-
资助金额:$270.0万
-
财政年份:2021
-
负责人:VESNA D GAROVIC
-
依托单位:
Mayo Clinic StARR Program
-
批准号:10443538
-
项目类别:
-
资助金额:$35.14万
-
财政年份:2020
-
负责人:VESNA D GAROVIC
-
依托单位:
Mayo Clinic StARR Program
-
批准号:10653867
-
项目类别:
-
资助金额:$34.53万
-
财政年份:2020
-
负责人:VESNA D GAROVIC
-
依托单位:
Hypertensive pregnancy disorders and future coronary artery disease
-
批准号:10452767
-
项目类别:
-
资助金额:$47.87万
-
财政年份:2018
-
负责人:VESNA D GAROVIC
-
依托单位:
Mayo Clinic Center for Clinical and Translational Science (CCaTS)
-
批准号:10674614
-
项目类别:
-
资助金额:$793.42万
-
财政年份:2017
-
负责人:VESNA D GAROVIC
-
依托单位:
Mayo Clinic Center for Clinical and Translational Science (CCaTS)
-
批准号:10632337
-
项目类别:
-
资助金额:$781.85万
-
财政年份:2017
-
负责人:VESNA D GAROVIC
-
依托单位:
VEGF Signaling in Endothelial and Glomerular Epithelial Cells in Preeclampsia
-
批准号:8236793
-
项目类别:
-
资助金额:$12.36万
-
财政年份:2008
-
负责人:VESNA D GAROVIC
-
依托单位:
VEGF Signaling in Endothelial and Glomerular Epithelial Cells in Preeclampsia
-
批准号:7846807
-
项目类别:
-
资助金额:$12.83万
-
财政年份:2008
-
负责人:VESNA D GAROVIC
-
依托单位:
VEGF Signaling in Endothelial and Glomerular Epithelial Cells in Preeclampsia
-
批准号:7368505
-
项目类别:
-
资助金额:$12.83万
-
财政年份:2008
-
负责人:VESNA D GAROVIC
-
依托单位:
VEGF Signaling in Endothelial and Glomerular Epithelial Cells in Preeclampsia
-
批准号:7589813
-
项目类别:
-
资助金额:$12.83万
-
财政年份:2008
-
负责人:VESNA D GAROVIC
-
依托单位:
VEGF Signaling in Endothelial and Glomerular Epithelial Cells in Preeclampsia
-
批准号:8051634
-
项目类别:
-
资助金额:$12.83万
-
财政年份:2008
-
负责人:VESNA D GAROVIC
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: